


# GioTag study: concept



# GioTag: design and results

**Patients (n=203):** received first-line afatinib followed by osimertinib after developing T790M-mediated resistance

**N=203 patients with EGFR+ NSCLC**

**Recruited from 10 countries**


**15%** of patients had ECOG PS of  $\geq 2$

**10%** had stable brain mets

**59%** Caucasian  
**25%** Asian  
**9%** African American

Data from electronic health records:  
**62%**

Manual chart review:  
**38%**



ECOG PS: Eastern Cooperative Oncology Group performance status; EGFR+: EGFR mutation-positive; OS: overall survival; TTF: time to treatment failure  
\*Based on an interim update analysis; only electronic health record data have been updated since the primary analysis (Hochmair et al. Future Oncol 2018;14:2861-74). Final analysis due in 2020.